Heart Device Patients Face 18% Major Bleeding Risk Over Five Years
New study reveals bleeding complications after heart procedure affect nearly 1 in 5 patients, with highest risk in first 6 months.
Summary
A major clinical trial following 1,833 patients for five years found that 18% experienced serious bleeding complications after receiving a left atrial appendage occlusion device, a heart procedure used to prevent strokes in patients who cannot take blood thinners. The bleeding risk was highest in the first six months after the procedure (20.5% annually) before dropping to 3.9% per year. Most bleeding events occurred in the digestive system, and patients who experienced major bleeding had significantly higher rates of stroke and death. Key risk factors included older age, female sex, diabetes, previous bleeding history, and kidney disease.
Detailed Summary
This landmark study addresses a critical safety concern for patients receiving left atrial appendage occlusion (LAAO), a heart procedure designed to prevent strokes in people who cannot safely take blood-thinning medications due to bleeding risks.
Researchers analyzed data from 1,833 patients who received either Amulet or Watchman heart devices between 2016-2019, following them for five years. The study used rigorous bleeding criteria requiring blood transfusion or significant hemoglobin drops to define major bleeding events.
The results revealed that 331 patients (18.1%) experienced major bleeding over five years, with an annual rate of 5.9%. Critically, bleeding risk was highest immediately after the procedure—20.5% per year in the first six months—then dropped substantially to 3.9% annually. Most bleeding events (88.8%) were unrelated to the procedure itself, with gastrointestinal bleeding accounting for the majority of cases. Independent risk factors included advancing age, female sex, diabetes, prior bleeding history, and kidney disease.
The implications for longevity and cardiovascular health are significant. Patients who experienced major bleeding had dramatically higher rates of stroke (14.7% vs 6.6%) and cardiovascular death (24.4% vs 12.9%), along with increased all-cause mortality (49.2% vs 25.4%). These findings suggest that bleeding complications may accelerate overall health decline and reduce lifespan, even in patients receiving devices specifically designed to prevent strokes while avoiding blood thinners.
Key Findings
- Major bleeding affected 18% of patients over 5 years, with highest risk in first 6 months
- Bleeding risk factors include older age, female sex, diabetes, and kidney disease
- Patients with bleeding had 2x higher stroke rates and nearly 2x higher mortality
- Most bleeding events were gastrointestinal, occurring even without blood thinners
Methodology
Randomized clinical trial of 1,833 patients receiving Amulet or Watchman devices from 2016-2019 with 5-year follow-up. Major bleeding defined using rigorous BARC criteria requiring transfusion or ≥3 g/dL hemoglobin drop.
Study Limitations
Study limited to specialized centers with experienced operators, potentially limiting generalizability. Patient population was already at high bleeding risk, making broader applicability uncertain.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.